Literature DB >> 12094265

Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.

M K Andersen, J Pedersen-Bjergaard, L Kjeldsen, I H Dufva, K Brøndum-Nielsen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12094265     DOI： 10.1038/sj.leu.2402634

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  Cytogenetic abnormalities without evidence of relapse after treatment with imatinib and stem cell transplantation in a patient with Ph-positive ALL.

Authors:  Miwa Sakai; Kazuteru Ohashi; Takeshi Kobayashi; Takuya Yamashita; Hideki Akiyama; Hisashi Sakamaki
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

2.  Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors.

Authors:  Monika Ribeiro de Mello Conchon; Israel Bendit; Patricia Ferreira; Walter Lima; Cristina Kumeda; Lucia Dias; Dalton de Alencar Fischer Chamone; Pedro Enrique Dorlhiac-Llacer
Journal:  Int J Hematol       Date:  2008-12-18       Impact factor: 2.490

3.  The -7 chromosomal abnormalities with signs of myelodysplasia in chronic myeloid leukemia as a major red signal.

Authors:  Emilie Cayssials; François Guilhot
Journal:  Haematologica       Date:  2019-06       Impact factor: 9.941

4.  Persistence of derivative chromosome 22 after achieving a major molecular response in chronic myeloid leukemia with a cryptic BCR-ABL1 fusion gene.

Authors:  Hiromichi Matsushita; Atsuko Masukawa; Satoshi Arakawa; Yoshiaki Ogawa; Satomi Asai; Miharu Yabe; Kiyoshi Ando; Hayato Miyachi
Journal:  Int J Hematol       Date:  2009-12-10       Impact factor: 2.490

Review 5.  Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.

Authors:  Vivian G Oehler; Jerald P Radich
Journal:  Curr Hematol Malig Rep       Date:  2006-09       Impact factor: 3.952

6.  Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.

Authors:  Sureyya Bozkurt; Burak Uz; Yahya Buyukasik; Ozlen Bektas; Ayten Inanc; Hakan Goker; Emin Kansu
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

7.  t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia.

Authors:  Marija Denčić-Fekete; Vesna Đorđević; Clelia Tiziana Storlazzi; Gradimir Janković; Andrija Bogdanović; Jelica Jovanović; Mariano Rocchi; Biljana Todorić-Živanović; Milica Strnad; Mirjana Gotić
Journal:  Int J Hematol       Date:  2009-03-26       Impact factor: 2.490

8.  Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform.

Authors:  Peter Valent; Thomas Lion; Dominik Wolf; Christian Sillaber; Hermine Agis; Andreas Petzer; Alois Lang; Peter Kalhs; Dietmar Geissler; Richard Greil; Werner Linkesch; Sonja Burgstaller; Josef Thaler; Günther Gastl
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

9.  Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.

Authors:  Wei Wang; Guilin Tang; Jorge E Cortes; Hui Liu; Di Ai; C Cameron Yin; Shaoying Li; Joseph D Khoury; Carlos Bueso-Ramos; L Jeffrey Medeiros; Shimin Hu
Journal:  J Hematol Oncol       Date:  2015-04-08       Impact factor: 17.388

10.  Secondary clonal hematologic neoplasia following successful therapy for acute promyelocytic leukemia (APL): A report of two cases and review of the literature.

Authors:  Daria Gaut; Joshua Sasine; Gary Schiller
Journal:  Leuk Res Rep       Date:  2018-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.